Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00319501 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 234
- Enrollment target
NCT00319501 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 234 participants.
The verdict
NCT00319501, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 234 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of diazepam in the management of refractory epilepsy in selected patients who require intermittent medical intervention for the control of episodes of acute repetitive seizures. In addition, to assess the support provided by caregivers who are not themselves or not under the direct supervision of health care professionals at the time of administration.
Interventions
- DRUG Placebo
- DRUG Vanquix Auto-Injector (Diazepam Injection)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2006-01 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00319501
The ClinicalTrials.gov registry entry for NCT00319501 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00319501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00319501 about?
NCT00319501 is a clinical study titled "Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.". To evaluate the efficacy and safety of diazepam in the management of refractory epilepsy in selected patients who require intermittent medical intervention for the control of episodes of acute repetitive seizures. In addition, to assess the support provided by caregivers who are not themselves or no...
What is the current status of trial NCT00319501?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 234 participants. The study started on 2006-01. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00319501?
The interventions under investigation include: Placebo (DRUG), Vanquix Auto-Injector (Diazepam Injection) (DRUG).
Who is sponsoring clinical trial NCT00319501?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.